trending Market Intelligence /marketintelligence/en/news-insights/trending/0v7MLuia8UBEEEQWsLFsWA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Eton Pharmaceuticals' injectable hypotension drug gets US FDA nod

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Eton Pharmaceuticals' injectable hypotension drug gets US FDA nod

Eton Pharmaceuticals Inc. received the U.S. Food and Drug Administration's approval for Biorphen to treat low blood pressure caused by the dilation of blood vessels due to anesthesia intake.

Biorphen, which is an injectable form of phenylephrine, can be administered without diluting, thus reducing the risk of medication errors waste caused due to overdrawing medication, Eton Pharmaceuticals said in an Oct. 22 press release.

Phenylephrine, which is a highly concentrated medication primarily used for its drying effect to increase blood pressure, is required to be manually diluted before a patient can have it. It could also be purchased from 503B compounding pharmacies, but because compounded drugs are not subjected to FDA review, they are often associated with higher risks of medication error, the company said.

Before the Deer Park, Ill.-based company received the regulator's approval, phenylephrine was the only approved medication available for lowering the anesthesia-induced low blood pressure.

Eton Pharmaceuticals CEO Sean Brynjelsen said the company plans to make Biorphen available to hospitals across the U.S. before 2019 end.